Please login to the form below

Not currently logged in
Email:
Password:

NICE to oversee GP quality indicators

NICE will oversee the annual reviewing of Quality and Outcomes Framework indicators for GPs from April 1.

The National Institute for Health and Clinical Excellence (NICE) will oversee the annual reviewing of Quality and Outcomes Framework (QOF) indicators for GPs from April 1.

This decision follows a 13-week consultation that included clinicians, patient organisations, NHS commissioners and the public.

A key part of NICE's role will involve the creation of an independent Primary Care Quality and Outcomes Framework Indicator Advisory Committee who will be responsible for reviewing existing indicators and recommending new ones. However, the final say on QOF indicators will be negotiated between the British Medical Association (BMA) and NHS employers.

Commenting on the announcement Val Moore, NICE implementation director said: "The purpose of NICE evidence-based guidance is to support professionals in making best use of NHS resources. It is sometimes confusing for professionals when different pieces of national guidance don't recommend the same things."

As part of its new role, NICE will collate information in order to prioritise new indicators based on evidence of clinical and cost-effectiveness. A facility on the NICE website will allow interested parties to submit potential public health and clinical priority topics. The Advisory Committee will consider these topics and their relative priorities.

19th March 2009

From: Healthcare

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Genesis Research

Genesis Research is an international HEOR and RWE research organization. A leader in evidence strategy, generation and communication, the company...

Latest intelligence

Main image2
Customers, content and change
By Dominic Tyer...
Report: Reinventing product and portfolio value for the biopharmaceutical industry
Gain practical advice on determining and communicating product and portfolio value, including why, in fast-paced and evolving markets, you need to consider the evidence requirements of a growing network of...
Neil Thompson
How AI is finally helping rare diseases gain more than just attention
By Neil Thompson...